A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
STIMULAN VG: Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.
Standard of Care: Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.
Study summary
The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
In order to be eligible to participate in this study, subjects must meet all of the following criteria:
1. Presenting with a Stage IV pressure ulcer requiring treatment of excision, bony debridement and flap coverage/primary closure.
2. Operative candidate for flap surgery or primary closure.
3. Presence of focal osteomyelitis as suggested by imaging to show extent of infection. Acceptable imaging techniques are Magnetic Resonance Imaging or CT scan.
4. Adults ≥ 18 years in age at the time of treatment.
5. Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
6. Ability of the subject or legal authorized representative to provide voluntary, signed and dated informed consent prior to any study-related procedures.
Subjects who meet any of the following criteria will be excluded from participating in this study:
1. Reasons contributing to pressure ulcer cannot be addressed.
2. Severe immunological compromised patients as determined by the clinician.
3. Patients with diffuse or widespread pelvic osteomyelitis that is not amenable to adequate margins for debridement.
4. Patients presenting with head pressure ulcers.
5. Current or recent history (within last 2 years) of active substance abuse (e.g., recreational drugs, narcotics, or alcohol) that in the judgement of the investigator, may compromise the participant's safety/recovery or ability to follow the trial procedures.
6. Current smoker.
7. Diabetic patient with Hba1C level above 9.
8. Allergy to any component of the investigational product, such as calcium sulfate, glycopeptide antibiotics (Vancomycin), or aminoglycoside antibiotics (Gentamicin).
9. Concurrent involvement in a study of another investigational product.
10. Pregnant or planning to become pregnant during study period.
11. Flexion contractures where patient cannot passively get full extension.
12. Uncontrolled muscle spasms.
13. Unable to comply with bedrest restriction or offloading requirements
14. Unable to provide consent.
15. Fecal or urinary incontinence with contamination of the wound.
16. Lower extremity pressure ulcer location that is vascularly compromised as defined by an Ankle Brachial Index ≤ 0.7 mm Hg OR toe brachial index ≤ 0.6 mm OR toe pressure ≤ 40 mm Hg OR transcutaneous oximetry ≤ 40 mm Hg \*
17. Investigator considers the participant to be clinically malnourished.
18. Any conditions with known hypercalcemia (\> 10.3 mg/dl) or posing a significant risk for developing hypercalcemia (i.e., Hyperparathyroidism).
19. Investigator believes trial participation may compromise safety of the participant or trial results.
* Patients presenting with lower extremity pressure ulcers that are vascularly compromised can be rescreened followed successful revascularization
Primary outcome measure(s)
Individual patient success and findings at the 8 week follow-up visit — 8 week An individual patient treatment will be considered a success if there is complete wound closure and healing at the surgical site at two consecutive visits 2 weeks apart.
Trial sites (9)
Facility
City
Region
Status
Advanced Foot Care, LLC
Phoenix
Arizona
Recruiting
Northwestern University Feinberg School of Medicine
Chicago
Illinois
Recruiting
Henry Ford Hospital
Detroit
Michigan
Recruiting
University of Mississippi Medical Center
Jackson
Mississippi
Recruiting
Missouri Orthopaedic Institute
Columbia
Missouri
Recruiting
University of Nebraska Medical Center
Omaha
Nebraska
Recruiting
Rutgers New Jersey Medical School
Newark
New Jersey
Recruiting
NYU Langone Hospital - Long Island Clinical Research Center
Mineola
New York
Recruiting
University of Pittsburgh, McGowan Institute for Regenerative Medicine
Pittsburgh
Pennsylvania
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.